PGICX
Price
$18.66
Change
+$0.11 (+0.59%)
Updated
Aug 6 closing price
Net Assets
135.38M
RMFCX
Price
$59.40
Change
+$0.01 (+0.02%)
Updated
Aug 6 closing price
Net Assets
108.54B
Interact to see
Advertisement

PGICX vs RMFCX

Header iconPGICX vs RMFCX Comparison
Open Charts PGICX vs RMFCXBanner chart's image
Virtus KAR Equity Income C
Price$18.66
Change+$0.11 (+0.59%)
VolumeN/A
Net Assets135.38M
American Funds American Mutual R3
Price$59.40
Change+$0.01 (+0.02%)
VolumeN/A
Net Assets108.54B
PGICX vs RMFCX Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
PGICX vs. RMFCX commentary
Aug 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PGICX is a Hold and RMFCX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RMFCX has more cash in the bank: 109B vs. PGICX (135M). PGICX pays higher dividends than RMFCX: PGICX (2.46) vs RMFCX (1.26). PGICX was incepted earlier than RMFCX: PGICX (28 years) vs RMFCX (23 years). PGICX (2.16) is less costly to investors than RMFCX (0.91). RMFCX is a more actively managed with annual turnover of: 31.00 vs. PGICX (17.00). RMFCX has a lower initial minimum investment than PGICX: RMFCX (250) vs PGICX (2500). PGICX annual gain was more profitable for investors over the last year : 13.83 vs. RMFCX (10.70). RMFCX return over 5 years is better than : 54.40 vs. PGICX (0.71).
PGICXRMFCXPGICX / RMFCX
Total Expense Ratio1.950.91214%
Annual Report Gross Expense Ratio2.160.91237%
Fund Existence28 years23 years-
Gain YTD9.6989.486102%
Front LoadN/AN/A-
Min. Initial Investment25002501,000%
Min. Initial Investment IRAN/AN/A-
Net Assets135M109B0%
Annual Yield % from dividends2.461.26196%
Returns for 1 year13.8310.70129%
Returns for 3 years13.9525.7054%
Returns for 5 years0.7154.401%
Returns for 10 years23.9878.6930%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LMOPX36.31N/A
N/A
Patient Opportunity C
MGINX10.78N/A
N/A
DWS Global Macro Inst
NSBFX64.62N/A
N/A
Nuveen Dividend Growth R6
NEQAX12.72N/A
N/A
Neuberger Berman U.S. Equity Impact A
REFGX7.97-0.01
-0.13%
Emerging Markets Equities Fund R-6